The diagnostic tool leverages patient clinical history to accurately predict UTIs, identify causative organisms (Enterobacteriaceae), and determine antibiotic resistance or susceptibility patterns without the need for traditional cultures. By reducing unwarranted clinical investigations, AMRx saves valuable time, effort, and resources. This efficiency is particularly beneficial in resource-limited settings.
Hyderabad, June 7th 2024 /ET HealthWorld/: Innominds announces its partnership with SCIINV Biosciences to introduce AMRx, an advanced AI/ML-driven digital diagnostic tool designed to combat the growing threat of antimicrobial resistance (AMR). This innovative tool promises to revolutionise the detection and treatment of antibiotic-resistant infections without the need for traditional cultures.
The World Health Organization has identified AMR as one of the top ten global health threats. The alarming statistics underscore the urgency of this issue: In 2019, AMR was responsible for an estimated 1.2 million deaths worldwide. By 2050, AMR-related fatalities could surge to 10 million annually. Every 45 seconds, a person succumbs to an antibiotic-resistant infection.
AMRx, developed by Innominds and SCIINV Biosciences, is a groundbreaking, culture-free companion diagnostic tool that utilises AI/ML to predict urinary tract infections (UTIs) and determine antibiotic resistance patterns based on patient clinical history. This patented technology represents a significant advancement in the fight against AMR.
The diagnostic tool leverages patient clinical history to accurately predict UTIs, identify causative organisms (Enterobacteriaceae), and determine antibiotic resistance or susceptibility patterns without the need for traditional cultures. By reducing unwarranted clinical investigations, AMRx saves valuable time, effort, and resources. This efficiency is particularly beneficial in resource-limited settings. It can be deployed as a clinical decision support tool, aiding healthcare professionals in making appropriate empirical antibiotic prescriptions, thereby enhancing the accuracy and effectiveness of treatment. The tool ensures early diagnosis and treatment of infections, significantly improving patient outcomes and reducing the spread of antibiotic-resistant bacteria.
Ravi Meduri, Executive Vice President, Digital and IP Solutions, Innominds, said, "Our partnership with SCIINV Biosciences and the development of AMRx marks a significant step forward in our mission to combat antimicrobial resistance and improve patient care globally."
“Traditional methods are falling short in the race against wildfire like proliferation of antimicrobial resistance. It’s imperative to harness advanced digital technologies (AI/ML/DL) to develop alternative diagnostic tools and therapeutic solutions. Innovative, easily scalable, and quickly implementable digital diagnostic tools and drug development platforms are of paramount importance in the age of devastating pandemics including silent AMR, " said Prof (Dr) Ranga Reddy Burri, Advisor, SCIINV Biosciences Ltd and President, Infection Control Academy of India.
